Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Thu, 26.09.2024
Evotec SE
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies
Hamburg, Germany, 26 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn [ … ]
Fri, 20.09.2024
Evotec SE
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb [ … ]
Tue, 03.09.2024
Evotec SE
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024
Distribution of responsibilities across other Management Board functions
Hamburg, Germany, 03 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, [ … ]
Wed, 07.08.2024
Evotec SE
Hamburg, Germany, 07 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The con [ … ]
Wed, 10.07.2024
Evotec SE
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases
Hamburg, Germany, 10 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and licens [ … ]
Mon, 08.07.2024
Evotec SE
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars
Additional biosimilars potentially to be added to Sandoz development pipeline
Further guarantees for Sandoz long-term commercial supply security
Hamburg, Germany, and Seattle, WA, USA, 8 July 2024:
Evotec SE [ … ]
Tue, 25.06.2024
Evotec SE
Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program
Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program
Manufacturing Optimization P [ … ]
Mon, 10.06.2024
Evotec SE
Most agenda items adopted with great majority
Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka
Hamburg, Germany, 10 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced [ … ]
Wed, 22.05.2024
Evotec SE
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER
STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024
POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR
RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEG [ … ]
Tue, 30.04.2024
Evotec SE
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES
STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS
JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY
Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based l [ … ]